Medline (NASDAQ:MDLN) Price Target Raised to $54.00

Medline (NASDAQ:MDLN) had its price target raised by BMO Capital Markets from $45.00 to $54.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other equities analysts also recently weighed in on the stock. BNP Paribas Exane initiated coverage on shares of Medline in a research note on Monday, January 12th. They issued a “neutral” rating and a $38.00 price target on the stock. Mizuho started coverage on Medline in a research report on Monday, January 12th. They issued an “outperform” rating and a $48.00 target price on the stock. Leerink Partners set a $56.00 price target on Medline in a research note on Wednesday. Evercore reissued an “outperform” rating and issued a $55.00 price target on shares of Medline in a research note on Wednesday. Finally, Rothschild & Co Redburn set a $42.00 price objective on shares of Medline in a research report on Monday, January 12th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Medline presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.35.

Medline Stock Down 2.8%

MDLN stock opened at $47.51 on Thursday. The stock’s 50 day moving average is $44.52. Medline has a 52 week low of $34.89 and a 52 week high of $50.88.

Medline (NASDAQ:MDLN) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.25). The business had revenue of $7.79 billion for the quarter, compared to analysts’ expectations of $7.52 billion. The company’s revenue for the quarter was up 14.8% on a year-over-year basis.

Insider Activity

In related news, Director Andrew J. Mills acquired 2,586,206 shares of the stock in a transaction dated Thursday, December 18th. The shares were acquired at an average price of $29.00 per share, with a total value of $74,999,974.00. Following the acquisition, the director owned 2,586,206 shares in the company, valued at approximately $74,999,974. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Charles N. Mills bought 2,579,310 shares of Medline stock in a transaction that occurred on Thursday, December 18th. The stock was bought at an average price of $29.00 per share, with a total value of $74,799,990.00. Following the completion of the acquisition, the director owned 2,441,379 shares in the company, valued at approximately $70,799,991. The trade was a -1,870.00% increase in their position. The disclosure for this purchase is available in the SEC filing.

Institutional Trading of Medline

Institutional investors and hedge funds have recently modified their holdings of the company. Sound Income Strategies LLC bought a new stake in shares of Medline during the 4th quarter worth $25,000. Entrust Financial LLC bought a new stake in Medline during the fourth quarter valued at about $26,000. NBC Securities Inc. bought a new stake in Medline during the fourth quarter valued at about $28,000. Global Retirement Partners LLC acquired a new stake in shares of Medline in the fourth quarter valued at about $31,000. Finally, North Star Investment Management Corp. bought a new position in shares of Medline in the fourth quarter worth about $36,000.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Citigroup raised its price target to $60 and kept a “buy” rating — a ~26.6% upside from the recent price, highlighting conviction after the quarter. Citigroup Raise
• Positive Sentiment: UBS increased its target to $57 and maintained a “buy” rating — ~20.2% upside — reflecting upgraded forecasts post-Q4. UBS Raise
• Positive Sentiment: BMO lifted its target to $54 and set an “outperform” rating (~13.9% upside), joining other brokers in boosting estimates after the quarter. BMO Raise
• Positive Sentiment: RBC raised its target to $53 with an “outperform” call (~11.8% upside), another vote of confidence from the street. RBC Raise
• Neutral Sentiment: Analysts broadly boosted forecasts after Q4 results; summary coverage aggregates the upgrades and modeling adjustments. Analysts Boost Forecasts
• Neutral Sentiment: Medline’s Q4 earnings call highlighted record sales and strategic innovations — supportive for revenue trajectory but mixed vs. EPS expectations. Earnings Call Highlights
• Neutral Sentiment: Full earnings call transcript is available for investors who want detail on guidance, margin commentary and management tone. Earnings Transcript
• Neutral Sentiment: Wells Fargo raised its target slightly to $47 but kept an “equal weight” rating — effectively neutral near-term guidance from this shop. Wells Fargo Note
• Negative Sentiment: Shares gapped down after what coverage labels a weak earnings print (EPS miss despite a revenue beat), which prompted the initial selloff. Shares Gap Down
• Negative Sentiment: As Medline transitions to public markets, the IPO/ESOP disclosures and management’s growth guidance drew public scrutiny — a source of near-term uncertainty for investors. IPO Scrutiny

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.